Genmab - ADR

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 – Genmab A/S (Nasdaq: GMAB) will hold its 2024 R&D Update and ASH Data Review Meeting today, December 11, 2024 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually in English and can be attended via live webcast.

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new long-term results from two ongoing clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with diffuse large B-cell lymphoma (DLBCL). Results from Arm 1 of the Phase 1b/2 EPCORE® NHL-2 trial (NCT04663347), evaluating fixed-duration epcoritamab in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), d.

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) who received epcoritamab monotherapy In the study, 75 percent of evaluable responders achieved undetectable minimal residual disease (MRD), indicating no detectable disease following.

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Genmab's shares are down to very attractive levels and hard to ignore. The company's royalty revenues are expected to exceed $2.5 billion this year and potentially $4 billion at peak, driven primarily by Darzalex and Kesimpta. Despite some setbacks and market concerns, Genmab's long-term growth prospects remain strong, supported by growing Epkinly revenues, expanding clinical pipeline and the acquisition of ProfoundBio.

Genmab Is Too Attractive To Ignore

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) following treatment with epcoritamab plus lenalidomide + rituximab (R2) Long-term follow-up results demonstrated strong and durable efficacy, with an estimated two-year overall survival (OS) rate of 90 percent Results f.

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has unveiled a licensing agreement with Genmab (CSE:GEN) that could generate up to $630 million in payments, alongside royalties. The deal gives the Danish biotech exclusive global rights to develop and commercialise a monoclonal antibody from the UK drug developer's GlyMab platform.

Scancell strikes deal worth up to $630m with Genmab

Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,355 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; December 3, 2024 –  Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Media Release COPENHAGEN, Denmark; November 25, 2024 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief F inancial O fficer Anthony Pagano will take part in a fireside chat at Citi's 2024 Global Healthcare Conference on December 3 , 202 4 at 8 :30 PM CET / 2 : 30 P M EST. A webcast of the event will be available on Genmab's website at https://ir.genmab.com/events-presentations.

Genmab to Present at Citi's Global Healthcare Conference

Company Announcement COPENHAGEN, Denmark; November 21, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 10,273 restricted stock units and 10,853 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab A/S (GMAB) Q3 2024 Earnings Conference Call November 6, 2024 12:00 PM ET Company Participants Jan van de Winkel - CEO Brad Bailey - EVP and Chief Commercial Officer Anthony Pagano - CFO Judith Klimovsky - Chief Development Officer Tahamtan Ahmadi - Chief Medical Officer Conference Call Participants Jonathan Chang - LeeRink Partners Paul Jeng - Guggenheim Securities, LLC Zain Ebrahim - JPMorgan Chase Suzanne van Voorthuizen - Kempen & Co. Xian Deng - UBS Yaron Werber - TD Securities Asthika Goonewardene - Truist Securities Yifeng Liu - HSBC Matthew Phipps - William Blair Alistair Campbell - RBC Capital Markets Vikram Purohit - Morgan Stanley Etzer Darout - BMO Capital Markets Operator Hello, and welcome to Genmab's Financial Results Conference Call for the First Nine Months of 2024. As a reminder, this conference call is being recorded.

Genmab A/S (GMAB) Q3 2024 Earnings Conference Call Transcript

November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY ® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy Genmab announced that it will assume sole responsibility for the continued development and potential commercialization of acasunlimab Genmab revenue increased 29% compared to the first nine months of 2023, to DKK 15,085 million Genmab 2024 financial guidance updated “The third quarter of 2024 presented Genmab with additional opportunities to progress towards our goal of fundamentally transforming the lives of people with cancer and other serious diseases. The additional approval for TEPKINLY, along with positive data presentations for our promising late-stage assets acasunlimab and rinatabart sesutecan (Rina-S), underscore the potential of our pipeline and our commitment to the development of innovative antibody-based therapeutics,” said Jan van de Winkel, Ph.D.

Genmab Announces Financial Results for the First Nine Months of 2024

Genmab's robust pipeline, strategic partnerships, and strong 2023 performance, led by DARZALEX and EPKINLY, bolster my bullish conviction despite ongoing legal disputes with Johnson & Johnson. The company's Q3 earnings on November 6th are crucial, with expectations of $817M in revenue and $0.33 EPS, potentially reversing the recent 20% share price drop. Investors should watch for updates on Genmab's pipeline, OpEx, and DARZALEX royalty trends, as well as the impact of the ProfoundBio acquisition.

Genmab: Looking To Manage My Position Around Q3 Earnings

Media Release COPENHAGEN, Denmark; November 5, 2024 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief Executive Officer , Jan van de Winkel, Ph.D. and C hief F inancial O fficer , Anthony Pagano will take part in a fireside chat at the Jefferies London Healthcare Conference on November 1 9 , 202 4 at 4:30 PM CET / 10 : 30 AM EST.

Genmab to Present at Jefferies London Healthcare Conference

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin's lymphoma (NHL) patients New and updated data from EPCORE® clinical trial program reinforce the potential of epcoritamab as a monotherapy and in combination to treat multiple B-cell malignancies across lines of therapy Genmab A/S (Nasdaq: GMAB) announced today more than 20 abstracts evaluating epc.

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Investors need to pay close attention to Genmab (GMAB) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Genmab (GMAB) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Genmab (GMAB) Stock Undervalued Right Now?

Company Announcement Net sales of DARZALEX ® in the third quarter of 2024 totaled USD 3,016 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; October 15, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ® (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by Johnson & Johnson were USD 3,016 million in the third quarter of 2024. Net trade sales were USD 1,684 million in the U.S. and USD 1,332 million in the rest of the world.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Incyte

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Genmab A/S Sponsored ADR (GMAB) or Incyte (INCY). But which of these two stocks presents investors with the better value opportunity right now?

GMAB or INCY: Which Is the Better Value Stock Right Now?

Genmab (GMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 4, 2024 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Baillie Gifford & Co has informed us that, as of October 3, 2024, Baillie Gifford & Co held the voting rights to 3,301,530 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights in Genmab A/S.   About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics.

Major Shareholder Announcement

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today new data from the Phase 1/2 study of rinatabart sesutecan (Rina-S), an investigational folate receptor-alpha (FRα)-targeted, Topo1 antibody-drug conjugate (ADC), demonstrated a confirmed objective response rate (ORR) of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every 3 weeks (Q3W), regardless of FRα expression levels. These data were from the dose expansion part of a multi-part stu.

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Media Release COPENHAGEN, Denmark; August 26, 2024 Genmab A/S (Nasdaq: GMAB ) a nnounced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 2 2 nd Annual Global Healthcare Conference at 1 : 05 P M E D T / 7 : 05 P M CEST on September 4 , 202 4.

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

BioNTech SE

Genmab's stock continues to struggle despite the strong progress of the company's commercial portfolio in the first half of the year. Epkinly is now FDA-approved for third-line+ follicular lymphoma, which should boost its revenue growth rates in the following quarters. BioNTech gave up on co-development of acasunlimab, but Genmab is undeterred and expects to start a phase 3 trial by the end of the year.

Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for the treatment of this patient population in the European Un.

News for Genmab - ADR Stock (GMAB)